Pharmaceuticals

Drug Development Biotechnology Drug Pricing Acquisitions Manufacturing Drug Manufacturing Vaccine Development Mergers and Acquisitions Corporate Governance Market Competition

Edgewise Reports Favorable Interim Safety in Phase 2 HCM Trial of EDG-7500

The readout underscores a clean cardiac safety profile, preserving the timeline for full Part D data in Q2 2026.

Telix Investors Urged to Seek Lead Plaintiff Status Before Jan. 9 in Securities Class Action

Sanofi to Acquire Dynavax for $2.2 Billion in Cash Tender Offer

CMS Unveils Voluntary BALANCE Program to Lower GLP-1 Costs for Medicare and Medicaid

Neurocrine’s Valbenazine Misses Phase 3 Goals in Dyskinetic Cerebral Palsy

Minnesota Jury Awards $65.5 Million to Woman in Johnson & Johnson Talc Cancer Case

White House Secures Nine More Drugmaker Pacts on MFN Pricing as TrumpRx Nears Launch

Medicare’s First Negotiated Drug Prices Take Effect Jan. 1, Cutting 2026 Costs

CEPI Puts Up to $54.3 Million Behind Moderna’s H5 mRNA Bird Flu Vaccine for Phase 3

Investor Firms Press Telix Shareholders as Lead-Plaintiff Deadline Nears

DBV Peanut Allergy Patch Succeeds in Pivotal Phase 3, Setting Up 2026 FDA Filing

Singapore’s Key Exports Rise 11.6% in November, Beating Forecasts on Pharma and Tech

Sanofi, Dren Bio Set Autoimmune Collaboration Worth Up to $1.7 Billion With $100 Million Upfront

Sanofi Ends PPMS Bid After Tolebrutinib Fails Phase 3 as FDA Delays Review for nrSPMS

First GLP‑1 Implant Trial for Obese Cats Begins With First Patient Dosed

Study Finds FDA Pivotal Trials Rarely Reflect U.S. Diversity as Black and Hispanic Enrollment Falls

Law Firms Urge Telix Investors To Seek Lead Role by Jan. 9 in Securities Class Action

Eli Lilly Picks Huntsville for $6 Billion API Plant to Supply Next-Gen Drugs

Formycon, Zydus Seal Exclusive Deal for Keytruda Biosimilar in U.S. and Canada

Pfizer Licenses Early-Stage Oral GLP-1 From YaoPharma in Up to $2 Billion Deal